Back to Journals » OncoTargets and Therapy » Volume 15

MicroRNA-139-3p Inhibits the Growth and Metastasis of Ovarian Cancer by Inhibiting ELAVL1 [Retraction]

Authors Xue F, Li QR, Xu YH, Zhou HB

Received 29 July 2022

Accepted for publication 29 July 2022

Published 2 August 2022 Volume 2022:15 Pages 839—840

DOI https://doi.org/10.2147/OTT.S384255



Xue F, Li QR, Xu YH, Zhou HB. Onco Targets Ther. 2019;12:8935–8945.

At the authors request, the Editor and Publisher of OncoTargets and Therapy wish to retract the published article. The authors notified the journal that the primers meant for miR-139-3p had mistakenly been designed for miR-129-3p and the conclusions described in the reported study were unreliable. In addition, it was also found that images in Figure 3 had been duplicated. Specifically,

  • Figure 3A, OVCAR-3, 0 h, miR-NC appears to have been duplicated with the same image for Figure 3A, OVCAR-3, 0 h, miR-139-3p.

The authors were unable to explain how the incorrect primers came to be designed or how the images in Figure 3A came be to be duplicated. The authors were also unable to provide the original data for their study. The Editor agreed with the authors request to retract the article.

Our decision-making was informed by our policy on publishing ethics and integrity and the COPE guidelines on retraction.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.